Magretta Adiamah Beth Poole Dr Janet Lindsey Dr Rebecca Hill Dr Helen Blair et al. | MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastoma | 2025 |
|
Dr Hayden Bell Dr Helen Blair Samantha Jepson Gosling Dr Martin Galler Dan Astley et al. | Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia | 2024 |
|
Dr Ricky Tirtakusuma Dr Paul Milne Dr Helen Blair Yuzhe Shi Dr Simon Bomken et al. | Fusion transcripts are present in early progenitor cells in KMT2A-rearranged B-ALL | 2024 |
|
Dan Coleman Dr Helen Blair Sandeep Potluri Professor Olaf Heidenreich
| Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1 | 2024 |
|
Dr Sarah Fordham Dr Wei-Yu Lin Dr Helen Blair Dr Claire Elstob Dr Hayden Bell et al. | Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia | 2023 |
|
Dr Paul Sinclair Dr Ruth Cranston Prahlad Raninga Joanna Cheng Rebecca Hanna et al. | Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia | 2023 |
|
Dr Hayden Bell Dr Helen Blair Mankaran Singh Professor Anthony Moorman Professor Olaf Heidenreich et al. | Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia | 2023 |
|
Dr Helen Blair Dr Katarzyna Szoltysek Rachel Cameron Professor Olaf Heidenreich
| The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML | 2023 |
|
Aaron Wilson Sean Hockney Sharon Angel Dr Helen Blair Dr Deepali Pal et al. | A human mesenchymal spheroid prototype to replace moderate severity animal procedures in leukaemia drug testing | 2022 |
|
Dr Jose Luis Marin-Rubio Dr Maria Duenas Fadic Dr Tiaan Heunis Dr Abeer Dannoura Dr Joe Inns et al. | A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia | 2022 |
|
Dr Ricky Tirtakusuma Dr Katarzyna Szoltysek Professor Vasily Grinev Dr Sirintra Nakjang Dr Daniel Williamson et al. | Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia | 2022 |
|
Dr Deepali Pal Dr Helen Blair Sean Hockney Dr Melanie Beckett Mankaran Singh et al. | hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia | 2022 |
|
Dr Toni Pringle Dr Corey Chan Dr Saimir Luli Dr Helen Blair Dr Kenneth Rankin et al. | Synthesis and In Vivo Evaluation of a Site-specifically Labeled Radioimmunoconjugate for Dual-Modal (PET/NIRF) Imaging of MT1-MMP in Sarcomas | 2022 |
|
Dr Natalie Bell Dr Helen Blair Dr Simon Bomken
| Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy | 2021 |
|
Yuzhe Shi Melanie Beckett Dr Helen Blair Dr Ricky Tirtakusuma Dr Sirintra Nakjang et al. | Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia | 2021 |
|
Mankaran Singh Dr Helen Blair Philip Berry Professor Olaf Heidenreich
| Multi-drug chemotherapy dose optimisation in preclinical leukaemia models using HPLC-MS/MS | 2020 |
|
Liz Matheson Huw Thomas Marian Case Dr Helen Blair Rosanna Jackson et al. | Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM | 2019 |
|
Dr Helen Blair Professor Christine Harrison FRCPath FMedSci Dr Lisa Russell
| Single cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia | 2019 |
|
Dr Helen Blair Professor Olaf Heidenreich
| Subtype-specific regulatory network rewiring in acute myeloid leukemia | 2019 |
|
Dr Deepali Pal Dr Helen Blair Professor Olaf Heidenreich
| Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia | 2019 |
|
Dr Paul Sinclair Dr Helen Blair Dr Sarra Ryan Dr Lars Buechler Joanna Cheng et al. | Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 | 2018 |
|
Dr Sarah Fordham Dr Helen Blair Dr Claire Elstob Professor Ruth Plummer Dr Yvette Drew et al. | Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase | 2018 |
|
Dr Lynsey McKenzie Hasan Issa Sandeep Potluri Dr Helen Blair Asmida Isa et al. | The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation | 2018 |
|
Dr Alex Elder Dr Simon Bomken Dr Ian Wilson Dr Helen Blair Dr Simon Cockell et al. | Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia | 2017 |
|
Dr Aiste McCormick Gavin Cuthbert Dr Rachel O'Donnell Dr Brian Wilson Huw Thomas et al. | Functional characterisation of a novel ovarian cancer cell line, NUOC-1 | 2017 |
|
Dr Richard Noble Dr Natalie Bell Dr Helen Blair Huw Thomas Nicole Phillips et al. | Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and burkitt lymphoma | 2017 |
|
Dr Britta Vormoor Yvonne Schlosser Dr Helen Blair Abhishek Sharma Sarah Wilkinson et al. | Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2 | 2017 |
|
Dr Lynsey McKenzie Dr Sirintra Nakjang Dr Helen Blair Professor Hermann Josef Vormoor Professor Olaf Heidenreich et al. | Identification of CCND2 As a RUNX1/ETO Target Required for Leukaemic Propagation | 2016 |
|
Dr Deepali Pal Dr Helen Blair Dr Alex Elder Katie Dormon Dr Kate Rennie et al. | Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia | 2016 |
|
Dr Alex Elder Dr Klaus Rehe Dr Simon Bomken Dr Paul Sinclair Katie Dormon et al. | The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts. | 2016 |
|
Dr Paul Sinclair Joanna Cheng Prahlad Raninga Rebecca Hanna Shaun Hollern et al. | A Targeted Functional Clone Tracking Assay for the Identification of Tumour Suppressor Genes in BCP- ALL Implicates the Transcription Factors FOXO3 and PRDM1 | 2015 |
|
Katie Dormon Elda Latif Dr Matthew Bashton Dr Deepali Pal Dr Helen Blair et al. | A Whole Genome In Vivo Crispr Screen in Primary ALL Predicts Leukaemic Relapse | 2015 |
|
Dr Alex Elder Dr Helen Blair Katie Dormon Dr Simon Bomken Dr Simon Cockell et al. | High Abundance of Acute Lymphoblastic Leukaemia Founder Clones Does Not Translate to Functional Heterogeneity | 2015 |
|
Dr Britta Vormoor Yvonne Schlosser Dr Helen Blair Sarah Wilkinson Professor Herbie Newell et al. | Inhibition of DNA-Repair Enzymes (DNA-Pk and Parp) to Sensitize Ewing Sarcoma to Chemo-And Radiotherapy | 2015 |
|
Dr Natalie Bell Dr Helen Blair Lisa Price Dr Katrina Wood Professor Hermann Josef Vormoor et al. | Patient-derived xenograft and in vivo bioluminescent modelling of B-cell NHL | 2015 |
|
Dr Britta Vormoor Henrike Knizia Michael Batey Dr Ian Wilson Dr Petra Dildey et al. | Development of a Preclinical Orthotopic Xenograft Model of Ewing Sarcoma and Other Human Malignant Bone Disease Using Advanced In Vivo Imaging | 2014 |
|
Dr Natalie Bell Dr Helen Blair Professor Hermann Josef Vormoor Dr Christopher Bacon Dr Vikki Rand et al. | Development of in Vivo Models of Paediatric Burkitt Lymphoma Allowing Therapeutic Target Analysis and Drug Testing | 2014 |
|
Dr Alex Elder Dr Simon Bomken Dr Helen Blair Professor Hermann Josef Vormoor Professor Olaf Heidenreich et al. | Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia | 2014 |
|
Dr Simon Bomken Dr Helen Blair Professor Hermann Josef Vormoor Professor Olaf Heidenreich
| Preclinical modelling of childhood acute lymphoblastic leukaemia | 2014 |
|
Professor Julie Irving Elizabeth Matheson Dr Helen Blair Marian Case Isabella Swidenbank et al. | Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition | 2014 |
|
Michael Batey Dr Frida Ponthan Dr Helen Blair Professor Olaf Heidenreich
| The development and evaluation of a series of novel in vivo imaging models of AML for the assessment of drug efficacy | 2014 |
|
Dr Mitsushiro Nakatomi Dr Helen Blair Katie MacArthur Dr Victor Ruiz-Perez Professor Judith Goodship et al. | Evc regulates a symmetrical response to Shh signaling in molar development | 2013 |
|
Dr Simon Bomken Dr Lars Buechler Dr Klaus Rehe Dr Frida Ponthan Dr Alex Elder et al. | Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression | 2013 |
|
Dr Helen Blair Dr Stuart Tompson Yu-Ning Liu Dr Jennifer Campbell Katie MacArthur et al. | Evc2 is a positive modulator of Hedgehog signalling that interacts with Evc at the cilia membrane and is also found in the nucleus | 2011 |
|
Dr Simon Bomken Dr Lars Buechler Dr Klaus Rehe Dr Frida Ponthan Dr Helen Blair et al. | Lentiviral Transduction of Patient Derived Leukaemic Blasts Allowing In Vivo Bioluminescent Monitoring in An NSG Model of Leukaemia Stem Cell Maintenance | 2011 |
|
Dr Helen Blair Dr Stuart Tompson Dr Jennifer Campbell Professor Judith Goodship
| Evc and Evc2 are interacting cilia transmembrane proteins that modulate Ihh signalling | 2009 |
|
Dr Victor Ruiz-Perez Dr Helen Blair Dr Colin Miles Dr Heiko Peters Professor Judith Goodship et al. | Evc is a positive mediator of Ihh-regulated bone growth that localises at the base of chondrocyte cilia | 2007 |
|
Dr Stuart Tompson Dr Victor Ruiz-Perez Dr Helen Blair Dr Michael Wright Professor Judith Goodship et al. | Sequencing EVC and EVC2 identifies mutations in two-thirds of Ellis-van Creveld syndrome patients | 2007 |
|
Dr Helen Blair Dr Mark Buddles Dr Ann Curtis Professor Judith Goodship
| Identification of a mutation in synapsin I, a synaptic vesicle protein, in a family with epilepsy | 2004 |
|
Professor Judith Goodship Dr Helen Blair Dr Mark Buddles Dr Ann Curtis
| Deficiency of synapsin I, a synaptic vesicle protein, causes epilepsy | 2003 |
|
Dr Victor Ruiz-Perez Dr Stuart Tompson Dr Helen Blair Dr Michael Wright Professor Judith Goodship et al. | Mutations in two nonhomologous genes in a head-to-head configuration cause Ellis-van Creveld syndrome | 2003 |
|
Dr Helen Blair Emeritus Professor Barry Hirst
| Targeting polymerised liposome vaccine carriers to intestinal M cells | 2001 |
|
Dr Helen Blair
| A phenotype map of the mouse X chromosome: Models for human X-linked disease | 2000 |
|
Dr Helen Blair
| Positioning of five genes (CASK, ARX, SAT, IMAGE cDNAs 248928 and 253949 from the human X chromosome short arm with respect to evolutionary breakpoints on the mouse X chromosome | 2000 |
|